Bridger Management buys $75,520,398 stake in DexCom (DXCM)

DexCom (DXCM) : Bridger Management scooped up 555,163 additional shares in DexCom during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 834,203 shares of DexCom which is valued at $75,520,398.DexCom makes up approximately 4.56% of Bridger Management’s portfolio.

Other Hedge Funds, Including , Millennium Management reduced its stake in DXCM by selling 116,392 shares or 28.05% in the most recent quarter. The Hedge Fund company now holds 298,599 shares of DXCM which is valued at $27,032,167. DexCom makes up approx 0.07% of Millennium Management’s portfolio. Cipher Capital Lp sold out all of its stake in DXCM during the most recent quarter. The investment firm sold 26,997 shares of DXCM which is valued $2,444,038.Rhumbline Advisers boosted its stake in DXCM in the latest quarter, The investment management firm added 7,767 additional shares and now holds a total of 94,511 shares of DexCom which is valued at $8,556,081. DexCom makes up approx 0.02% of Rhumbline Advisers’s portfolio.Her Majesty The Queen In Right Of The Province Of Alberta… boosted its stake in DXCM in the latest quarter, The investment management firm added 38,430 additional shares and now holds a total of 50,020 shares of DexCom which is valued at $4,545,317. DexCom makes up approx 0.06% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio.Proficio Capital Partners boosted its stake in DXCM in the latest quarter, The investment management firm added 4 additional shares and now holds a total of 5 shares of DexCom which is valued at $461.

DexCom opened for trading at $91.3 and hit $91.93 on the upside on Thursday, eventually ending the session at $91.71, with a gain of 0.68% or 0.62 points. The heightened volatility saw the trading volume jump to 6,75,001 shares. Company has a market cap of $7,693 M.

On the company’s financial health, DexCom reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.12. The company had revenue of $137.30 million for the quarter, compared to analysts expectations of $132.54 million. The company’s revenue was up 47.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.05 EPS.

Many Wall Street Analysts have commented on DexCom. Company shares were Reiterated by The Benchmark Company on Aug 3, 2016 to “Buy”, Firm has raised the Price Target to $ 106 from a previous price target of $86 .

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *